ATI RN
ATI Pharmacology Proctored Exam
1. A client with OCD has a new prescription for Paroxetine. Which of the following instructions should the nurse include?
- A. It can take several weeks before you feel like the medication is helping.
- B. Take the medication just before bedtime to promote sleep.
- C. You should take the medication when needed for obsessive urges.
- D. Monitor for weight gain while taking this medication.
Correct answer: A
Rationale: The correct instruction for the nurse to include when teaching a client with OCD who has a new prescription for Paroxetine is that it can take several weeks before the client feels like the medication is helping. Paroxetine, like other selective serotonin reuptake inhibitors (SSRIs), can take 1 to 4 weeks before the client reaches the full therapeutic benefit. Therefore, it is important to inform the client about this delay in onset of action to manage their expectations and promote adherence to the treatment plan. Choices B, C, and D are incorrect because taking Paroxetine before bedtime is not necessary, it should be taken consistently at the same time each day; Paroxetine is usually taken regularly, not as needed; and while monitoring weight is important, it is not a specific instruction related to the onset of action for Paroxetine.
2. A client is receiving combination chemotherapy. Which of the following findings should the nurse identify as an indication of an oncologic emergency?
- A. Dry oral mucous membranes
- B. Nausea and vomiting
- C. Temperature of 38.1°C (100.6°F)
- D. Anorexia
Correct answer: C
Rationale: A temperature of 38.1°C (100.6°F) can indicate an infection, which is considered an oncologic emergency in clients receiving chemotherapy due to the increased risk of sepsis in immunocompromised individuals. Dry oral mucous membranes (Choice A), nausea and vomiting (Choice B), and anorexia (Choice D) are common side effects of chemotherapy but do not typically indicate an oncologic emergency requiring immediate intervention.
3. A healthcare professional is monitoring a client who is receiving spironolactone. Which of the following findings should the professional report to the provider?
- A. Serum Sodium 144 mEq/L
- B. Urine output 120 mL in 4 hours
- C. Serum Potassium 5.2 mEq/L
- D. Blood Pressure 140/90 mm Hg
Correct answer: C
Rationale: A serum potassium level of 5.2 mEq/L indicates hyperkalemia, which is a potentially dangerous condition. Spironolactone, a potassium-sparing diuretic, can cause potassium retention, leading to hyperkalemia. This electrolyte imbalance can result in serious consequences such as cardiac dysrhythmias. The healthcare professional should promptly report this finding to the provider, withhold the medication, and take appropriate actions to prevent complications. Monitoring and managing potassium levels are crucial in clients receiving spironolactone. The other options do not directly relate to the potential adverse effects of spironolactone and are within normal limits, making them less urgent to report.
4. While reviewing a client's medical history, a healthcare professional notes a prescription for Digoxin. Which of the following findings is a manifestation of Digoxin toxicity?
- A. Elevated blood pressure
- B. Bradycardia
- C. Yellow-tinged vision
- D. Ringing in the ears
Correct answer: C
Rationale: Yellow-tinged vision is a visual disturbance associated with Digoxin toxicity, often accompanied by other symptoms like nausea, vomiting, and confusion. Bradycardia is a common therapeutic effect of Digoxin, while elevated blood pressure and ringing in the ears are not typically associated with Digoxin toxicity. Therefore, the correct answer is yellow-tinged vision as a manifestation of Digoxin toxicity.
5. A client has a new prescription for Adalimumab for Rheumatoid Arthritis. Based on the route of administration of Adalimumab, which of the following should the nurse plan to monitor?
- A. The vein for thrombophlebitis during IV administration.
- B. The subcutaneous site for redness following injection.
- C. The oral mucosa for ulceration after oral administration.
- D. The skin for irritation following removal of transdermal patch.
Correct answer: B
Rationale: Adalimumab is administered subcutaneously for Rheumatoid Arthritis. Injection-site reactions such as redness and swelling are common. Therefore, the nurse should monitor the subcutaneous site for redness following the injection to assess for potential adverse effects.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access